We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Algorithm Listens To Patients Pass Urine for Assessing Urinary Tract Symptoms

By LabMedica International staff writers
Posted on 05 Jul 2022

Lower urinary tract symptoms, problems related to the working of the bladder and the urethra, are common and affect an estimated 60% of men and 57% of women. More...

Uroflowmetry is an important tool for the assessment of patients with symptoms, but patients have to urinate into a machine during outpatient visits. They are asked to urinate into a funnel connected to the uroflowmeter which records information about flow. During the COVID-19 pandemic access to clinics has been restricted, and even where patients can attend, the test can take a long time with queues to use a single machine. Now, an artificial intelligence (AI) algorithm trained to listen to patients pass urine can identify abnormal flows and could be a useful and cost-effective means of monitoring and managing urology patients at home.

The deep learning tool, Audioflow, that was developed by researchers at the Singapore General Hospital (Singapore) performed almost as well as a specialist machine used in clinics, and achieved similar results to urology residents in assessing urinary flow. The current study focused on sound created by urine in a soundproof environment, but the ambition is to create an app so patients can monitor themselves at home. In order to train and validate the algorithm, the researchers recruited 534 male participants between December 2017 and July 2019 to it. Participants used the usual uroflowmetry machine in a soundproofed room, and recorded their urination using a smartphone.

Using 220 recordings, the AI learned to estimate flow rate, volume, and time which can indicate when there is an obstruction or if the bladder is not working well. It was trained to listen to and analyze male urinary flow which is different from that of women and would need a separate sample to learn to analyze female urination. The results were compared to a conventional uroflowmetry machine and to a panel of six urology residents who separately graded the dataset. The AI agreed with conventional uroflowmetry for over 80% of recordings, and compared to the specialist urologists and external residents for identification of abnormal flows, it achieved an 84% rate of agreement. Audioflow will now be rolled out as a smartphone app via primary care physicians so it can be tested in the real world and learn from different datasets in different noise environments.

“There is a trend towards using machine learning in many fields, because clinicians do not have a lot of time. At the same time, particularly since the pandemic there is a shift towards telemedicine and less hospital-based care. We were keen to develop a way to monitor our patients to see how they are doing between hospital visits,” said Dr. Lee Han Jie from the Singapore General Hospital who led the development of the algorithm. “Our AI can outperform some non-experts and comes close to senior consultants. But the real benefit is having the equivalent of a consultant in the bathroom with you, every time you go. We are now working towards the algorithm being able to work when there is background noise in the normal home environment and this will make the true difference for patients.”

“Giving patients the ability to measure urinary flow at home is more comfortable for them and reduces time waiting in the clinic,” said Christian Gratzke, Professor of Urology at University Hospital Freiburg and member of the EAU22 Scientific Congress Committee of Urology. “This is a well-executed study with a significant number of patients and represents a promising approach to developing a portable app that can be used at home. I look forward to seeing the real-world results.”

Related Links:
Singapore General Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Drug Testing Assays
Atellica DT 250 Analyzer
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.